Abstract
AstraZeneca plc is developing tesaglitazar, an oral dual peroxisome proliferator-activated receptor alpha/gamma agonist, for the potential improvement of dyslipidemia and glycemic control in type 2 diabetic patients.
MeSH terms
-
Alkanesulfonates / chemical synthesis
-
Alkanesulfonates / metabolism
-
Alkanesulfonates / pharmacology
-
Alkanesulfonates / therapeutic use*
-
Animals
-
Clinical Trials as Topic
-
Humans
-
PPAR alpha / agonists*
-
PPAR gamma / agonists*
-
Patents as Topic
-
Phenylpropionates / chemical synthesis
-
Phenylpropionates / metabolism
-
Phenylpropionates / pharmacology
-
Phenylpropionates / therapeutic use*
-
Structure-Activity Relationship
Substances
-
Alkanesulfonates
-
PPAR alpha
-
PPAR gamma
-
Phenylpropionates
-
tesaglitazar